OnKure Therapeutics, Inc. (OKUR) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
the bull case· 2
75
managers reporting a position in thirteen f filings showing broad institutional interest
13fJun 30 '26+17.17%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '26the bear case· 2
4 of 20
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '2615
managers whose positions together make up four fifths of the reported value
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 9 '26 report. Not a forecast, not advice.
We are a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. Using a structure- and computational chemistry-driven drug design platform, we are committed to improving clinical outcomes for patients by building a robust pipeline of small-molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.
OnKure Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
High 2.98 at 1:15 pm ET, low 2.93 at 3:30 pm ET.
OKUR (OnKure Therapeutics, Inc.) has 2 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
75 managers report a position worth $159.0M between them, and 15 of them hold 80% of it.
tall tick = annual report · 1 on record
OnKure Therapeutics, Inc. has no measured co-movers clearing our correlation floor, so only its SEC classification is shown.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.